



	Congress Hall A1	Congress Hall A2	Auditorium 10-11-12	C1-M1-2	Auditorium 15	Congress Hall A3	C1-M3	C1-M4	C1-M5	C1-M0
08.00-09.30	<b>S 7.1 Hot and new in transplantation : selected topics from 2017/18</b>	<b>S 4.9 CKD - new therapeutic approaches</b>	<b>S 3.1 Membranous nephropathy - the evolving story</b>	<b>S 6.2 Optimising clinical outcomes and technique survival</b>	<b>S 5.2 The non-dialysis pathway in ESRD</b>	<b>FC 01 Salt and related issues</b>	<b>FC 02 Cardiovascular complications in dialysis</b>	<b>FC 03 History of nephrology</b>		
09.30-10.45	<i>Posters, coffee break and exhibition visit</i>									<b>BOEHRINGER INGELHEIM</b>
10.45-11.30	<b>PL 2 Klaus Olgaard: New paradigms of the kidney - Vascular-bone axis in CKD</b>									
11.30-11.45	<i>Break</i>									
11.45-13.15	<b>S 0.2 - Late Breaking Clinical Trials</b>	<b>S 4.2 Progression of chronic kidney disease – hot issues beyond blood pressure and renin-angiotensin system</b>	<b>S 6.3 Optimising fluid management in PD patients</b>	<b>S 5.9 DOPPS - The sweet truth: Optimizing care in advanced CKD and dialysis with a focus on diabetic patients</b>	<b>S 3.6 Glomerular disease in the omics era</b>	<b>FC 04 AKI experimental</b>	<b>FC 05 Clinical nephrology 1</b>	<b>FC 06 CKD rehabilitation</b>	<b>FC 07 Clinical hypertension 1</b>	
13.15-14.45		<b>VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA</b>	<b>BAXTER HEALTHCARE</b>	<b>FRESENIUS MEDICAL CARE</b>	<b>AMGEN EUROPE</b>	<b>DANONE NUTRICIA RESEARCH</b>	<b>ASTRAZENECA PHARMACEUTICAL S LP</b>	<b>SANOI-GENZYME</b>	<b>MSD</b>	<b>PACE-RESVERLOGIX</b>
15.00-16.30	<b>S 0.4 ASN Highlights</b>	<b>S 3.5 Lupus and vasculitis - therapy</b>	<b>S 5.3 Uremic toxicity - New insights</b>	<b>S 8.2 A new life for sodium in Nephrology</b>	<b>S 1.1 Renal physiology - tubular transport</b>	<b>FC 08 Renal pathology 1</b>	<b>FC 09 Biomarkers in CKD</b>	<b>FC 10 Bone disease in HD</b>	<b>FC 11 Transplantation epidemiology</b>	
16.30-17.00	<i>Posters, coffee break and exhibition visit</i>									
17.00-18.30	<b>S 8.3 Diabetic nephropathy</b>	<b>S 5.7 Treatment of CKD-MBD</b>	<b>0.5 ERA-EDTA &amp; Japanese Society of Nephrology</b>	<b>S 7.3 Expanding the donor pool (deceased and live donors) KPD, ABOi, machine perfusion</b>	<b>S 4.8 n-3 PUFA in CKD: Does it matter?</b>	<b>FC 12 Clinical nephrology 2</b>	<b>FC 13 Genetic diseases</b>	<b>FC 14 CKD risk and progression</b>	<b>FC 15 AKI clinical 1</b>	
18.45-19.45							<b>SIEMENS HEALTHINEERS</b>			<b>ZYDUS TRANS-IMMUNE (A DIVISION OF CADILA HEALTHCARE)</b>

	Congress Hall A1	Congress Hall A2	Auditorium 10-11-12	C1-M1-2	Auditorium 15	Congress Hall A3	C1-M3	C1-M4	C1-M5	C1-M0
08.00-09.30	<b>S 8.1 Hot topics in hypertension</b>	<b>S 5.5 Neurologic disturbances in CKD</b>	<b>S 4.1 Update in plasmapheresis for treating kidney diseases</b>	<b>S 2.2 Pediatric nephrology</b>	<b>S 9.2 AKI in various circumstances</b>	<b>FC 16 Anaemia in CKD</b>	<b>FC 17 Diabetes clinical</b>	<b>FC 18 Transplantation treatment</b>		
09.30-10.45	<i>Poster session, coffee break and exhibition visit</i>						<b>ASAHI KASEI MEDICAL EUROPE</b>	<b>OTSUKA PHARMACEUTICAL EUROPE</b>	<b>ERA-EDTA General Assembly</b>	<b>SHIRE INTERNATIONAL</b>
10.45-11.30	<b>PL 3 Bruce Sullenger: From the RNA world to the clinic: RNAs as drugs and drug targets</b>									
11.30-11.45	<i>Coffee break and exhibition visit</i>									
11.45-13.15	<b>S 4.7 CKD as a public health priority: organizational models</b>	<b>0.6 ERA-EDTA &amp; Chinese Society of Nephrology</b>	<b>0.8 ERA-EDTA &amp; European Society for Paediatric Nephrology</b>	<b>S 9.3 Renal Replacement Therapy in the Intensive Care Unit</b>	<b>0.1 ERA-EDTA Registry</b>	<b>FC 19 Glomerulonephritis 1</b>	<b>FC 20 CKD epidemiology</b>	<b>FC 21 CKD-MBD</b>		
13.15-14.45		<b>VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA</b>	<b>BAXTER HEALTHCARE</b>	<b>ALEXION PHARMACEUTICALS</b>	<b>B.BRAUN AVITUM</b>	<b>ASTRAZENECA PHARMACEUTICALS LP</b>	<b>TERUMO BCT</b>	<b>NXSTAGE MEDICAL</b>	<b>MEDICE ARZNEIMITTEL PUETTER</b>	<b>AMICUS THERAPEUTICS</b>
15.00-16.30	<b>S 6.4 Home hemodialysis in Europe 2018</b>	<b>S 5.6 Cardiovascular calcifications in CKD</b>	<b>S 4.6 Focus on surrogate end-points in Nephrology</b>	<b>S 3.3 Plasma cell dyscrasias and the kidney</b>	<b>S 1.2 Mitochondria: critical players in kidney disorders</b>	<b>FC 22 Renal pathology 2</b>	<b>FC 23 Clinical hypertension 2</b>	<b>FC 24 Extracorporeal treatment</b>	<b>FC 25 Inflammation in CKD</b>	
16.30-17.00	<i>Posters, coffee break and exhibition visit</i>									
17.00-18.30	<b>S 2.1 Recent findings in ADPKD</b>	<b>S 5.1 Scheduling dialysis and hemodiafiltration in 2018: a new portfolio?</b>		<b>S 7.2 Humoral immunity (HLA and non-HLA)</b>	<b>S 4.3 New biomarkers of CKD progression</b>	<b>FC 26 Cell biology</b>	<b>FC 27 Glomerulonephritis 2</b>	<b>FC 28 AKI Clinical 2</b>	<b>FC 29 Outcome in dialysis</b>	

	Congress Hall A1	Congress Hall A2	Auditorium 10-11-12	C1-M1-2	Auditorium 15	Congress Hall A3	C1-M3	C1-M4	C1-M5	C1-M0
08.00- 09.30	<b>S 5.8</b> The diagnosis of Heart Failure in End Stage Kidney Disease (ESKD): a lingering dilemma	<b>S 3.2 IgA nephropathy: from genes to therapeutic controversies</b>	<b>S 7.4 Post transplantation diabetes mellitus - relation to obesity and new options/challenges</b>	<b>S 9.1 AKI biomarkers and risk factors</b>	<b>0.7 ERA-EDTA &amp; European Society of Hypertension</b>	<b>S 2.3 Pregnancy, CKD and hypertension</b>	<b>S 4.4 Interstitial fibrosis and mechanisms of CKD progression</b>	<b>FC 30 Nutrition in CKD</b>	<b>FC 31 Vascular access</b>	<b>FC 32 Peritoneal dialysis</b>
09.30-09.45	<i>Break</i>									
09.45-10.30	<b>PL 4 Marcello Tonelli: Epidemiology of kidney disease</b>									
10.30-10.45	<i>Coffee break</i>									
10.45-12.15	<b>S 5.4 New methods of anaemia management in CKD patients</b>	<b>S 7.5 Risk profiling in renal transplant patients</b>	<b>S 3.4 Rituximab in immune mediated glomerular diseases: one drug does not fit all</b>	<b>S 4.5 Controversy: too much Nephrology?</b>	<b>S 6.1 Lessons from International Databases (in collaboration with ISPD)</b>	<b>S 1.3 APOL1 impact in kidney disease</b>	<b>FC 33 Renal development and cystic diseases</b>	<b>FC 34 Acid-base balance and uric acid</b>	<b>FC 35 Diabetes basic research</b>	<b>FC 36 Paediatric nephrology</b>
12.15-12.30	<i>Break</i>									
12.30-14.00	<b>SS 1 Nephrology Pearls</b>									

- Fluids and electrolytes, tubular transport, physiology
- Hereditary disorders, development, pregnancy, paediatric nephrology
- Glomerular diseases and general clinical nephrology
- Chronic Kidney Disease: pathophysiology, epidemiology, prevention, progression, aging
- End Stage Renal Disease and dialysis
- Home therapies, peritoneal dialysis
- Transplantation and immunology
- Hypertension, diabetes, vascular diseases
- Acute Kidney Injury and intensive care nephrology